logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Fudosteine CAS 13189-98-5

Fudosteine CAS 13189-98-5

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 13189-98-5

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
13189-98-5
Appearance::
Off-white Crystalline
Molecular Formula::
C6H13NO3S
Molecular Weight::
179.23700
EINECS NO::
NA
MDL NO::
MFCD00899873
CAS NO::
13189-98-5
Appearance::
Off-white Crystalline
Molecular Formula::
C6H13NO3S
Molecular Weight::
179.23700
EINECS NO::
NA
MDL NO::
MFCD00899873
Fudosteine CAS 13189-98-5

Product Description:

Product Name: Fudosteine CAS NO: 13189-98-5

 

 

Synonyms:

Fudosteine (R)-2-Amino-3-(3-hydroxypropylthio)propionic acid;

(2R)-2-amino-3-(3-hydroxypropylsulfanyl)propanoic acid;

(r)-2-amino-3-(3-hydroxypropylthio)propionic acid;

 

 

Chemical & Physical Properties:

Appearance: Off-white crystalline

Assay :≥99.0%

Density: 1.301 g/cm3

Boiling Point: 354.5℃ at 760 mmHg

Melting Point: 210.9-212.5℃

Flash Point: 168.2℃

Refractive Index: 1.558

Vapor Pressure: 1.92E-06mmHg at 25℃

Storage Condition: -20℃ Freezer

 

 

Fudosteine is a novel mucoactive agent and a MUC5AC mucin hypersecretion inhibitor.Target: OthersFudosteine is a cysteine derivative that is used as an expectorant in chronic bronchial inflammatory disorders. The administration of fudosteine during the challenge with ovalbumin prevented the development of airway hyperresponsiveness and accumulation of lymphocytes in the airways. Eotaxin, IL-4, and TGF-β levels and the relative intensity of matrix metalloproteinase-2 and matrix metalloproteinase-9 (MMP-2 and MMP-9) in BAL fluid were reduced by the fudosteine treatment; however, the number of eosinophils in BAL fluid and serum IgE levels did not change. The expression of TGF-β, the development of goblet cell hyperplasia, subepithelial collagenization, and basement membrane thickening were also reduced by the fudosteine treatment. Fudosteine inhibits MUC5AC mucin hypersecretion by reducing MUC5AC gene expression and the effects of fudosteine are associated with the inhibition of extracellular signal-related kinase and p38 mitogen-activated protein kinase in vivo and extracellular signal-related kinase in vitro.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.